Shunt surgery and lecanemab therapy in patients with idiopathic normal pressure hydrocephalus and alzheimer's disease: a report of two cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41729309.
- Also identified by DOI 10.1007/s00701-026-06804-8 and PMC identifier 12932390.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Idiopathic normal pressure hydrocephalus (iNPH) is a condition in the elderly commonly treated with ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. iNPH frequently coexists with Alzheimer's disease (AD), for which anti-amyloid-β antibodies such as lecanemab have recently become available. Because lecanemab may cause hemorrhagic imaging abnormalities, the timing of shunt surgery in relation to antibody therapy raises concern regarding perioperative bleeding risk. Here, we report two patients with iNPH and AD treated with different sequences of shunt surgery and lecanemab. No hemorrhagic complications were observed, although conclusions regarding safety should be interpreted cautiously.
Medical subject headings
- Hydrocephalus, Normal Pressure
- Alzheimer Disease
- Ventriculoperitoneal Shunt
- Cerebrospinal Fluid Shunts